Boston Scientific Corporation to acquire Bolt Medical for $664m.

Boston Scientific Corporation, a medical technologies company, agreed to acquire Bolt Medical, the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease, for $664m. "Representing one of the fastest growing medical device segments, intravascular lithotripsy therapy addresses a significant unmet need for patients with complex calcified arterial disease through a minimally invasive approach. Bolt Medical is developing a next-generation technology that is highly complementary to our existing portfolio. The addition of this system to our offerings can help us better serve physicians and their patients and provides a platform for future innovation," Lance Bates, Boston Scientific senior vice president and president, Interventional Cardiology Therapies.